Research Triangle Park, NC, United States of America

Mark A Paulik

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Research Triangle Park, NC (US) (2019 - 2023)
  • Boston, MA (US) (2024)

Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Mark A Paulik in Therapeutic Polypeptides

Introduction

Mark A Paulik is a notable inventor based in Research Triangle Park, NC (US). He has made significant contributions to the field of therapeutic polypeptides, holding a total of four patents. His work primarily focuses on developing long-acting glucagon-like polypeptide-1 (GLP-1) receptor agonists and glucagon-receptor selective polypeptides.

Latest Patents

One of his latest patents is titled "Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use." This invention pertains to isolated polypeptides that serve as long-acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides exhibit beneficial physicochemical properties compared to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides. These properties include longer elimination half-lives, improved solubility, and enhanced thermal stability. The invention also outlines methods for utilizing these GLP-1 receptor agonist polypeptides in treating metabolic diseases, such as type 2 diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD).

Another significant patent is "Glucagon-receptor selective polypeptides and methods of use thereof." This invention involves isolated polypeptides that are selective analogs for the human glucagon receptor. These analogs demonstrate improved solubility, thermal stability, and physicochemical properties compared to native endogenous glucagon. The invention also discusses methods for using these polypeptides in various therapeutic and diagnostic applications, particularly in treating obesity, diabetes, and metabolic disorders.

Career Highlights

Mark A Paulik has worked with several prominent companies in the biotechnology sector, including Intarcia Therapeutics, Inc. and I2o Therapeutics, Inc. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.

Collaborations

Throughout his career, Mark has collaborated with notable professionals in the field, including William Blackwell and Ved P Srivastava. These collaborations have likely enhanced his research and development efforts in therapeutic polypeptides.

Conclusion

Mark A Paulik's contributions to the field of therapeutic polypeptides are significant and impactful. His innovative patents and collaborations reflect his dedication to advancing medical

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…